Lymphoproliferative syndrome
MONDO:0016537A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis).
Also known as: lymphoproliferative disorder, lymphoproliferative syndrome
137 clinical trials for this condition and its sub-types, 69 tagged with Lymphoproliferative syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Lymphoproliferative syndrome
-
Castleman disease 8 trials · 18 incl. sub-types
4 sub-types
- Multicentric Castleman disease 13 trials
- Idiopathic multicentric Castleman disease 3 trials Sub-types →
- Localized Castleman disease 1 trial
- Pediatric Castleman disease 0 trials
-
Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types
9 sub-types
- Autoimmune lymphoproliferative syndrome type 4 3 trials
- FAS-related autoimmune lymphoproliferative syndrome 2 trials
- Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency 1 trial
- Castleman-Kojima disease 0 trials
- Autoimmune lymphoproliferative syndrome type 1 0 trials
- Autoimmune lymphoproliferative syndrome type 2A 0 trials
- Autoimmune lymphoproliferative syndrome type 2B 0 trials
- Autoimmune lymphoproliferative syndrome, type III caused by mutation in PRKCD 0 trials
- Type 3 autoimmune lymphoproliferative syndrome 0 trials
-
X-linked lymphoproliferative syndrome 7 trials · 11 incl. sub-types
2 sub-types
-
Lymphoproliferative syndrome 1 0 trials
-
Lymphoproliferative syndrome 2 0 trials
-
New stem cell transplant trial aims to control tough lymphoma
Disease control OngoingThis study tests a stem cell transplant to control peripheral T-cell lymphoma in people whose cancer has not responded to standard treatments. Participants receive a donor's stem cells after chemotherapy or antibody therapy to prepare their body. The goal is to see if this approa…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Experimental drug combo tested for rare, deadly castleman disease
Disease control OngoingThis study looks at a rare disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers are testing several drug combinations, including chemotherapy and antivirals, to see if they can control the disease. The study also tracks how the dis…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for Tough-to-Treat blood cancers: targeted pill shows promise
Disease control OngoingThis phase 2 trial tests the drug venetoclax (a pill) in 110 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study includes two groups: those with a specific genetic change (17p deletion) and those who have failed oth…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Lower drug dose after transplant may cut infections without losing protection
Disease control OngoingThis study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New transplant recipe may tame Graft-Versus-Host disease in blood cancer patients
Disease control OngoingThis study tests a specific timing of chemotherapy drugs (busulfan and fludarabine) before a donor stem cell transplant, followed by cyclophosphamide after the transplant, to treat high-risk blood cancers like leukemia and lymphoma. The goal is to reduce the chance of the transpl…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New cell therapy targets Epstein-Barr virus in immune-compromised patients
Disease control OngoingThis study tests an experimental cell therapy called tabelecleucel in 190 people with diseases caused by the Epstein-Barr virus (EBV), including certain lymphomas and post-transplant complications. The treatment uses specially prepared immune cells to fight the virus. The main go…
Phase 2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could tree sap heal skin sores? new trial in PNG tests ancient remedy
Disease control OngoingThis study tests whether sap from the Pterocarpus indicus tree can help heal small skin ulcers (sores) in remote areas of Papua New Guinea. 222 people with sores smaller than a dime will get either the plant sap, Savlon antiseptic cream, or no treatment. Researchers will check he…
Phase 2 • Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Supercharged immune cells take on tough lymphomas
Disease control OngoingThis study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment involves taking a patient's own T cells (a type of immune cell), adding a gene that helps them recognize and attack lymphoma cell…
Phase 1/2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Engineered t cells with a kill switch aim to make stem cell transplants safer
Disease control OngoingThis study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causin…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Suicide Gene-Equipped t cells aim to make stem cell transplants safer
Disease control OngoingThis trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-ho…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Hope for aggressive lymphoma: targeted drug added to chemo in major trial
Disease control OngoingThis Phase 3 trial tests whether adding the targeted drug acalabrutinib to standard chemotherapy (R-CHOP) helps people with a specific, aggressive type of lymphoma (non-GCB DLBCL) live longer without their cancer getting worse. About 611 adults aged 18 to 75 who have not been tre…
Phase 3 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Stem cell transplant offers new hope for kids with rare immune diseases
Disease control OngoingThis study tests a donor stem cell transplant for people with severe immune system problems, like SCID and Wiskott-Aldrich syndrome. The goal is to help the body make healthy blood cells and fight infections. Participants receive donated stem cells to rebuild their immune system.…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at tough lymphomas in first human test
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial,…
Phase 1/2 • Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Supercharged immune cells aim to stop lymphoma comeback
Disease control OngoingThis early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo shows promise for Hard-to-Treat CLL
Disease control OngoingThis phase II study tests a combination of two drugs, venetoclax and rituximab, in 25 people with chronic lymphocytic leukemia (CLL) that has relapsed or not responded to treatment. The goal is to see how well the combination works and how safe it is. Participants receive venetoc…
Phase 2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Can a new immune system fix T-Cell diseases? trial tests donor transplants
Disease control OngoingThis study tests whether a stem cell transplant from a healthy donor can safely treat people with severe T-cell problems. Participants receive chemotherapy and antibody therapy before the transplant, followed by donor stem cells. The goal is to see if the new immune system can co…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for blood cancer patients: using mismatched donors for transplants
Disease control OngoingThis study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…
Phase 2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Targeted radiation shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…
Phase 2 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Milder stem cell transplant shows promise for kids with immune disorders
Disease control OngoingThis study tests a stem cell transplant using a milder chemotherapy-like regimen to treat children and young adults (up to age 28) with various immune system disorders. The goal is to help the donor stem cells settle in the body with fewer side effects. The study involves 20 part…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a new tracer light up cancer growth?
Diagnosis OngoingThis trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…
Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Scientists hunt for hidden genes behind family blood cancer clusters
Knowledge-focused OngoingThis long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive study aims to uncover hidden triggers of blood cancers
Knowledge-focused By invitation onlyThis study is collecting blood, bone marrow, and tissue samples from 5,000 people with blood cancers like leukemia and lymphoma. Researchers will analyze the samples to find genetic abnormalities that cause cancer cells to grow. The goal is to understand why these cancers develop…
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
21,000 lymphoma patients join landmark study to uncover what really affects survival
Knowledge-focused By invitation onlyThis study follows 21,000 adults newly diagnosed with non-Hodgkin lymphoma to learn which factors—like genetics, lifestyle, and treatment—affect survival and quality of life. Researchers will track health outcomes over time without providing a new treatment. The goal is to improv…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Researchers examine rare Post-Transplant cancer to improve future care
Knowledge-focused OngoingThis study reviews medical records of 241 adults who developed a rare cancer called PTLD after an organ or stem cell transplant. Researchers aim to understand patient survival, disease features, and current treatments. No new treatments are tested; the goal is to gather informati…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC